• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by ThermoGenesis Holdings Inc.

    8/15/24 3:53:44 PM ET
    $THMO
    Medical Specialities
    Industrials
    Get the next $THMO alert in real time by email
    NT 10-Q 1 thmo20240815_nt10q.htm FORM NT 10-Q thmo20240815_nt10q.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM 12b-25

     


     

    NOTIFICATION OF LATE FILING

     

    SEC FILE NUMBER: 333-82900
             CUSIP NUMBER: 88362L100

     

    (Check One)    

     

    ☐Form 10-K     ☐  Form 20-F     ☐  Form 11-K     ☒ Form 10-Q

    ☐Form 10-D     ☐  Form N-CEN     ☐  Form N-CSR

       
       

    For Period Ended: June 30, 2024

       
       

    ☐Transition Report on Form 10-K

       

    ☐Transition Report on Form 20-F

       

    ☐Transition Report on Form 11-K

       

    ☐Transition Report on Form 10-Q

       
       

    For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: ____________________

     

    PART I — REGISTRANT INFORMATION

     

    ThermoGenesis Holdings, Inc.


    (Full Name of Registrant)

     


    (Former Name if Applicable)

     

    2890 Kilgore Road


    (Address of Principal Executive Office (Street and Number))

     

    Rancho Cordova, California 95670


    (City, State and Zip Code)

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     

    (a)

    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

         
    ☐ 

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

         
     

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The Registrant has been unable without unreasonable effort or expense, to timely complete its financial statements and related disclosures required to be included in its quarterly report on Form 10-Q for the quarter ended June 30, 2024, due to the change of financial personnel.

     

    PART IV — OTHER INFORMATION

     

    (1)

    Name and telephone number of person to contact in regard to this notification

     

    Xiaochun “Chris” Xu

     

    (916)

     

    858-5100

    (Name)

     

    (Area Code)

     

    (Telephone Number)

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).    ☒  Yes    ☐   No

     

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?     ☐   Yes       ☒    No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    THERMOGENESIS HOLDINGS, INC.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Date: August 15, 2024

         

    By

     

    /s/ Xiaochun “Chris” Xu

                 
                Xiaochun “Chris” Xu
                Chief Executive Officer

     

     
    Get the next $THMO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THMO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Xu Xiaochun converted options into 7,894,737 shares (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    7/9/24 7:02:58 PM ET
    $THMO
    Medical Specialities
    Industrials

    Xu Xiaochun converted options into 4,113,158 shares (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    3/19/24 2:09:52 PM ET
    $THMO
    Medical Specialities
    Industrials

    Xu Xiaochun sold $612,000 worth of shares (600,000 units at $1.02) (SEC Form 4)

    4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)

    11/21/23 7:30:22 AM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $THMO
    SEC Filings

    View All

    ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel

    11/13/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    RANCHO CORDOVA, Calif., Sept. 6, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET, during the H.C. Wainwright 25th Annual Global Investment Conference, taking place September 11-13, 2023, in New York.  Dr. Xu will also host in-person and virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. Those interested in meeting wit

    9/6/23 8:30:00 AM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf

    8/10/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    1/6/25 5:30:21 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form NT 10-Q filed by ThermoGenesis Holdings Inc.

    NT 10-Q - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    8/15/24 3:53:44 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)

    8/6/24 5:20:08 PM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Financials

    Live finance-specific insights

    View All

    ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel

    11/13/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf

    8/10/23 4:05:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    ThermoGenesis Holdings to Announce Financial Results for the Second Quarter ended June 30, 2023 and Provide a Corporate Strategic Update

    Conference Call to be Held on August 10, 2023 RANCHO CORDOVA, Calif., Aug. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call

    8/8/23 3:26:00 PM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Leadership Updates

    Live Leadership Updates

    View All

    Atlantic Therapeutics Announces the Appointment of Russell Medford MD, PhD as New US-Based Chairman

    BOSTON, July 27 2022 Appointment aligns with recognized high growth potential for INNOVO® in the US.A strong endorsement for the scientific and clinical credibility of INNOVO® as an accessible treatment for Stress Urinary Incontinence (SUI).Endorses FemTech as a high potential investment category./PRNewswire/ -- Today Atlantic Therapeutics, a Galway, Ireland and Boston, USA-based MedTech innovator, announces the appointment of Russell Medford MD, PhD as Chairman. The addition of Dr Medford to the Board is a significant step to fulfill the potential of the INNOVO® brand in the large and under-served US stress urinary incontinence (SUI) market. Dr Medford is a senior healthcare and life scien

    7/27/22 7:00:00 AM ET
    $THMO
    Medical Specialities
    Industrials

    $THMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    11/27/23 8:10:20 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    8/14/23 4:27:10 PM ET
    $THMO
    Medical Specialities
    Industrials

    SEC Form SC 13D/A filed by ThermoGenesis Holdings Inc. (Amendment)

    SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)

    4/10/23 6:14:26 PM ET
    $THMO
    Medical Specialities
    Industrials